On this page
Current Australian answer (checked 7 October 2026): Australian pharmacists must not compound medicines containing GLP-1 receptor agonist analogues. The prohibition took effect on 1 October 2024. It applies to this ingredient class—not merely to a particular brand—and sits separately from the rules for supplying registered products such as Ozempic, Wegovy, Saxenda, Trulicity and Mounjaro.
A medicine can be TGA-registered, compounded, imported, or supplied through an unapproved-goods pathway. These are different legal and quality categories. A prescription, laboratory report or “custom” label does not automatically move a product into the registered-medicine category.
GLP-1 compounding rule at a glance
| Question | Australian position | What to verify |
|---|---|---|
| Can an Australian pharmacist compound a GLP-1 analogue? | No, under the class prohibition effective 1 October 2024 | Current TGA compounding guidance |
| Does a prescription override the prohibition? | No | A prescription does not displace manufacturing and supply law |
| Is a registered branded product “compounded”? | No | Check its ARTG entry, sponsor and approved Product Information |
| Does overseas manufacture avoid Australian rules? | No automatic exemption | Importation, advertising and supply rules must be assessed separately |
| Does a COA establish lawful supply? | No | Identity testing and regulatory status answer different questions |
This guide explains public regulatory material. It is not legal, prescribing or treatment advice.
Why Australia prohibited GLP-1 compounding
The TGA announced the change after concerns about the large-scale compounding of products promoted as alternatives to registered GLP-1 medicines. Compounding exemptions are designed for genuine individualised clinical needs; they are not an alternative mass-manufacturing system.
The prohibition closes the pharmacy-compounding route for GLP-1 receptor agonist analogues. It does not ban properly registered medicines, and it does not change the approved indications or PBS restrictions of branded products.
Registered medicine versus compounded product
| Feature | ARTG-registered medicine | Compounded preparation |
|---|---|---|
| Pre-market TGA assessment | Product-specific assessment and registration | Generally relies on a limited exemption rather than product registration |
| Approved sponsor and labelling | Recorded on the ARTG | Prepared for a particular context under compounding rules |
| Batch manufacturing framework | Registered supply chain and applicable GMP controls | Not equivalent to registration of a mass-supplied product |
| Current GLP-1 position | Permitted when the product is registered and lawfully supplied | Australian pharmacists must not compound GLP-1 analogues |
What the rule covers
The TGA wording concerns medicines containing GLP-1 receptor agonist analogues. The regulated class includes medicines used for type 2 diabetes or chronic weight management. Brand indications and subsidy differ, but those differences do not create a compounding exception.
For brand status, use the Australian GLP-1 approval and PBS hub. For the decision systems, use the TGA, ARTG, PBAC and PBS explainer.
What the rule does not prove
- It does not show that every product labelled “compounded” contains the stated ingredient.
- It does not make an overseas product TGA-registered.
- It does not establish that a product is sterile, potent or clinically suitable.
- It does not convert a laboratory certificate into regulatory approval.
- It does not answer whether a particular registered brand is PBS-subsidised.
How to verify a GLP-1 product claim
- Search the exact product name and sponsor on the ARTG.
- Match the ingredient, presentation and ARTG number—not just the molecule name.
- Read the approved Australian Product Information.
- Check the live PBS schedule separately if subsidy is claimed.
- If “compounded”, “custom”, “research” or imported wording appears, check the TGA’s current unapproved-goods and compounding guidance.
Frequently asked questions
Can a pharmacy compound semaglutide in Australia?
The TGA states pharmacists must not compound medicines containing GLP-1 receptor agonist analogues.
What about a shortage?
The current class prohibition is not presented as a routine shortage workaround. Check current TGA guidance rather than relying on overseas rules.
Does a doctor’s prescription make compounding legal?
No. Prescribing and manufacturing/supply obligations are separate.
Is tirzepatide included?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Use current TGA guidance and the registered product record; do not assume a product is exempt because it is dual-acting.
Does a COA make the product approved?
No. A COA may report tests on a sample. It does not create ARTG registration, lawful supply or clinical approval.
Primary Australian sources
- TGA: manufacturing, supplying and advertising compounded medicines lawfully — updated guidance published 14 May 2026.
- TGA: unapproved therapeutic goods.
- Australian Register of Therapeutic Goods.
Editorial status: Knowledge-only. Sources checked 7 October 2026. No product, dosing, sourcing or treatment recommendation is provided.
How to cite this article
Compounded GLP-1 Australia (2026): What the TGA Rules Actually Say. Elite Peps Australia. Published 7 October 2026; updated 7 October 2026. https://elitepepsaustralia.com/compounded-glp-1-australia-2026-what-the-tga-rules-actually-say/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.